Novel endoscopic papillectomy for reducing postoperative adverse events (with videos)
Lei Jiang,En-Qiang Ling-Hu,Ning-Li Chai,Wen Li,Feng-Chun Cai,Ming-Yang Li,Xu Guo,Jiang-Yun Meng,Xiang-Dong Wang,Ping Tang,Jing Zhu,Hong Du,Hong-Bin Wang
DOI: https://doi.org/10.3748/wjg.v26.i40.6250
IF: 5.374
2020-10-28
World Journal of Gastroenterology
Abstract:Pancreatic adenoma can potentially transform into adenocarcinoma, so it is recommended to be resected surgically or endoscopically. Endoscopic papillectomy is one of the main treatments for papillary adenoma, and bleeding, perforation, and pancreatitis are the most frequent and critical adverse events that restrict its wider use. There is no standard procedure for endoscopic papillectomy yet. The procedure is relevant to postoperative adverse events.To reduce the postoperative adverse event rates and improve patients' postoperative condition, we developed a standard novel procedure for endoscopic papillectomy.The novel endoscopic papillectomy had two main modifications based on the conventional method: The isolation of bile from pancreatic juice with a bile duct stent and wound surface protection with metal clips and fibrin glue. We performed a single-center retrospective comparison study on the novel and conventional methods to examine the feasibility of the novel method for reducing postoperative adverse events.A total of 76 patients, of whom 23 underwent the novel procedure and 53 underwent the conventional procedure, were retrospectively evaluated in this study. The postoperative bleeding and pancreatitis rates of the novel method were significantly lower than those of the conventional method (0 20.75%, = 0.028, and 17.4% 41.5%, = 0.042, respectively). After applying the novel method, the most critical adverse event, perforation, was entirely prevented, compared to a prevalence of 5.66% with the conventional method. Several postoperative symptoms, including fever, rapid pulse, and decrease in hemoglobin level, were significantly less frequent in the novel group ( = 0.042, 0.049, and 0.014, respectively). Overall, the total adverse event rate of the novel method was lower (0 24.5%, = 0.007) than that of the conventional method.Patients who underwent the novel procedure had lower postoperative adverse event rates. This study demonstrates the potential efficacy and safety of the novel endoscopic papillectomy in reducing postoperative adverse events.
gastroenterology & hepatology